Cargando…

Target modulation and pharmacokinetics/pharmacodynamics translation of the BTK inhibitor poseltinib for model-informed phase II dose selection

The selective Bruton tyrosine kinase (BTK) inhibitor poseltinib has been shown to inhibit the BCR signal transduction pathway and cytokine production in B cells (Park et al. Arthritis Res. Ther. 18, 91, 10.1186/s13075-016-0988-z, 2016). This study describes the translation of nonclinical research st...

Descripción completa

Detalles Bibliográficos
Autores principales:	Byun, Joo-Yun, Koh, Yi T., Jang, Sun Young, Witcher, Jennifer W., Chan, Jason R., Pustilnik, Anna, Daniels, Mark J., Kim, Young Hoon, Suh, Kwee Hyun, Linnik, Matthew D., Lee, Young-Mi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8455565/ https://www.ncbi.nlm.nih.gov/pubmed/34548595 http://dx.doi.org/10.1038/s41598-021-98255-7

Ejemplares similares

P1157: PHASE II STUDY OF GLOFITAMAB, POSELTINIB AND LENALIDOMIDE IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE B CELL LYMPHOMAS
por: Min Byun, Ja, et al.
Publicado: (2023)

Safety, pharmacokinetics, and pharmacodynamics of BMS-986142, a novel reversible BTK inhibitor, in healthy participants
por: Lee, Sun Ku, et al.
Publicado: (2017)

Comparison of the pharmacokinetics and pharmacodynamics of YH4808 in healthy subjects for defining an appropriate dosing regimen
por: Yoon, Sukyong, et al.
Publicado: (2021)

Multiple-dose pharmacokinetics and pharmacodynamics of evogliptin (DA-1229), a novel dipeptidyl peptidase IV inhibitor, in healthy volunteers
por: Gu, Namyi, et al.
Publicado: (2014)

Translational Pharmacokinetic‐Pharmacodynamic Modeling and Simulation: Optimizing 5‐Fluorouracil Dosing in Children With Pediatric Ependymoma
por: Daryani, VM, et al.
Publicado: (2016)

Pharmacokinetic and Pharmacodynamic Considerations in Antimalarial Dose Optimization
por: White, Nicholas J.
Publicado: (2013)

Dissecting the Pharmacodynamics and Pharmacokinetics of MSCs to Overcome Limitations in Their Clinical Translation
por: Salvadori, Michela, et al.
Publicado: (2019)

Considerations for Dose Selection and Clinical Pharmacokinetics/Pharmacodynamics for the Development of Antibacterial Agents
por: Rizk, M. L., et al.
Publicado: (2019)

Clinical Pharmacokinetics and Pharmacodynamics of Pazopanib: Towards Optimized Dosing
por: Verheijen, Remy B., et al.
Publicado: (2017)

Cancer Immunotherapy Dosing: A Pharmacokinetic/Pharmacodynamic Perspective
por: Le Louedec, Félicien, et al.
Publicado: (2020)

Evaluation of Natalizumab Pharmacokinetics and Pharmacodynamics: Toward Individualized Doses
por: Serra López-Matencio, Jose M., et al.
Publicado: (2021)

Pharmacokinetics and pharmacodynamics of repeat dosing of gabapentin in adult horses
por: Gold, Jenifer R., et al.
Publicado: (2022)

The pharmacokinetics and pharmacodynamics of esomeprazole in sheep after intravenous dosing
por: Smith, Joe S., et al.
Publicado: (2023)

The influence of dietary sodium content on the pharmacokinetics and pharmacodynamics of fimasartan
por: Gu, Namyi, et al.
Publicado: (2016)

Dose Optimization of Meropenem in Patients on Veno-Arterial Extracorporeal Membrane Oxygenation in Critically Ill Cardiac Patients: Pharmacokinetic/Pharmacodynamic Modeling
por: Kang, Soyoung, et al.
Publicado: (2022)

Low-dose Btk inhibitors: an ‘aspirin’ of tomorrow?
por: Payrastre, Bernard, et al.
Publicado: (2021)

Translational Pharmacokinetic/Pharmacodynamic Analysis of MYO‐029 Antibody for Muscular Dystrophy
por: Singh, P, et al.
Publicado: (2016)

Translational Pharmacokinetic/Pharmacodynamic Modeling and Simulation of Oxaliplatin and Irinotecan in Colorectal Cancer
por: Zhu, Jinwei, et al.
Publicado: (2023)

Effects of Age and Sex on the Single-Dose Pharmacokinetics and Pharmacodynamics of Apixaban
por: Frost, Charles E., et al.
Publicado: (2015)

Evaluation of Amikacin Pharmacokinetics and Pharmacodynamics for Optimal Initial Dosing Regimen
por: Kato, Hideo, et al.
Publicado: (2017)

Pharmacokinetics and Pharmacodynamics of High-Dose Piperacillin–Tazobactam in Obese Patients
por: Veillette, John J., et al.
Publicado: (2021)

Pharmacokinetic and pharmacodynamic evaluation according to absorption differences in three formulations of ibuprofen
por: Shin, Dongseong, et al.
Publicado: (2017)

Safety, tolerability, pharmacokinetic, and pharmacodynamic characteristics of vutiglabridin: A first‐in‐class, first‐in‐human study
por: Na, Joo Young, et al.
Publicado: (2022)

Pharmacokinetic/pharmacodynamic parameters of vancomycin for predicting clinical outcome of enterococcal bacteremia
por: Nham, Eliel, et al.
Publicado: (2022)

Translational Pharmacokinetic–Pharmacodynamic Modeling of NaV1.7 Inhibitor MK-2075 to Inform Human Efficacious Dose
por: Ballard, Jeanine E., et al.
Publicado: (2021)

Pharmacokinetics and Pharmacodynamics of Posaconazole
por: Chen, Lu, et al.
Publicado: (2020)

Pharmacokinetics and Pharmacodynamics of Ibrexafungerp
por: McCarthy, Matthew William
Publicado: (2021)

Pharmacokinetics and Pharmacodynamics of Tedizolid
por: Iqbal, Khalid, et al.
Publicado: (2022)

Emerging Insights for Translational Pharmacokinetic and Pharmacokinetic-Pharmacodynamic Studies: Towards Prediction of Nose-to-Brain Transport in Humans
por: Ruigrok, Mitchel J. R., et al.
Publicado: (2015)

HM71224, a selective Bruton’s tyrosine kinase inhibitor, attenuates the development of murine lupus
por: Kim, Yu-Yon, et al.
Publicado: (2017)

Homogeneous BTK Occupancy Assay for Pharmacodynamic Assessment of Tirabrutinib (GS-4059/ONO-4059) Target Engagement
por: Yu, Helen, et al.
Publicado: (2018)

Pharmacokinetic and Pharmacodynamic Characteristics of Pelubiprofen Tromethamine vs. Pelubiprofen in Healthy Subjects
por: Son, Yu-Jeong, et al.
Publicado: (2023)

Pharmacokinetic/pharmacodynamic modeling for the determination of a cimicoxib dosing regimen in the dog
por: Jeunesse, Elisabeth C, et al.
Publicado: (2013)

Pharmacokinetics and Pharmacodynamics with Extended Dosing of CC-486 in Patients with Hematologic Malignancies
por: Laille, Eric, et al.
Publicado: (2015)

Pharmacokinetics and pharmacodynamics of a single dose Nilotinib in individuals with Parkinson's disease
por: Pagan, Fernando L., et al.
Publicado: (2019)

Introduction: lefamulin and pharmacokinetic/pharmacodynamic rationale to support the dose selection of lefamulin
por: Rodvold, Keith A
Publicado: (2019)

Pharmacokinetic/Pharmacodynamic Considerations of Alternate Dosing Strategies of Tocilizumab in COVID-19
por: Leung, Elizabeth, et al.
Publicado: (2021)

Pharmacokinetics, pharmacodynamics and safety assessment of multiple doses of soticlestat in healthy volunteers
por: Wang, Shining, et al.
Publicado: (2022)

Translational Pharmacokinetic/Pharmacodynamic Modeling of Tumor Growth Inhibition Supports Dose‐Range Selection of the Anti–PD‐1 Antibody Pembrolizumab
por: Lindauer, A, et al.
Publicado: (2016)

Translational pharmacokinetic‐pharmacodynamic modeling of preclinical and clinical data of the oral MET inhibitor tepotinib to determine the recommended phase II dose
por: Xiong, Wenyuan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_td9necq86t88pe8rgjla2de0d2